Ion Beam Applications SA
Ion Beam Applications SA IBAB.BR Peers
See (IBAB.BR) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IBAB.BR | €11.66 | +2.10% | 338.7M | 37.29 | €0.31 | +2.08% |
| PHIA.AS | €20.79 | +1.86% | 19.5B | 79.08 | €0.26 | +3.59% |
| EAPI.PA | €3.19 | +10.53% | 295.4M | -2.25 | -€1.38 | N/A |
| GBT.PA | €22.15 | +0.91% | 274.8M | 17.17 | €1.27 | +2.29% |
| ALERS.PA | €25.20 | -0.20% | 252.6M | 64.74 | €0.39 | N/A |
| ALCOR.PA | €35.10 | +0.29% | 154.5M | -234.00 | -€0.15 | N/A |
| SEQUA.BR | €1.40 | -9.21% | 87.8M | -1.69 | -€0.91 | N/A |
| AFME.PA | €1.31 | +3.56% | 48M | -3.10 | -€0.41 | N/A |
| ALNOV.PA | €0.49 | -0.41% | 35.2M | -0.78 | -€0.64 | N/A |
| ALMDT.PA | €1.61 | +6.06% | 32.5M | -1.23 | -€1.37 | N/A |
Stock Comparison
IBAB.BR vs PHIA.AS Comparison
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 338.7M. In comparison, PHIA.AS has a market cap of 19.5B. Regarding current trading prices, IBAB.BR is priced at €11.66, while PHIA.AS trades at €20.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 37.29, whereas PHIA.AS's P/E ratio is 79.08. In terms of profitability, IBAB.BR's ROE is +0.09%, compared to PHIA.AS's ROE of +0.03%. Regarding short-term risk, IBAB.BR is more volatile compared to PHIA.AS. This indicates potentially higher risk in terms of short-term price fluctuations for IBAB.BR.
IBAB.BR vs EAPI.PA Comparison
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 338.7M. In comparison, EAPI.PA has a market cap of 295.4M. Regarding current trading prices, IBAB.BR is priced at €11.66, while EAPI.PA trades at €3.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 37.29, whereas EAPI.PA's P/E ratio is -2.25. In terms of profitability, IBAB.BR's ROE is +0.09%, compared to EAPI.PA's ROE of -0.14%. Regarding short-term risk, IBAB.BR is less volatile compared to EAPI.PA. This indicates potentially lower risk in terms of short-term price fluctuations for IBAB.BR.
IBAB.BR vs GBT.PA Comparison
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 338.7M. In comparison, GBT.PA has a market cap of 274.8M. Regarding current trading prices, IBAB.BR is priced at €11.66, while GBT.PA trades at €22.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 37.29, whereas GBT.PA's P/E ratio is 17.17. In terms of profitability, IBAB.BR's ROE is +0.09%, compared to GBT.PA's ROE of +0.04%. Regarding short-term risk, IBAB.BR is less volatile compared to GBT.PA. This indicates potentially lower risk in terms of short-term price fluctuations for IBAB.BR.
IBAB.BR vs ALERS.PA Comparison
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 338.7M. In comparison, ALERS.PA has a market cap of 252.6M. Regarding current trading prices, IBAB.BR is priced at €11.66, while ALERS.PA trades at €25.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 37.29, whereas ALERS.PA's P/E ratio is 64.74. In terms of profitability, IBAB.BR's ROE is +0.09%, compared to ALERS.PA's ROE of +0.02%. Regarding short-term risk, IBAB.BR is more volatile compared to ALERS.PA. This indicates potentially higher risk in terms of short-term price fluctuations for IBAB.BR.
IBAB.BR vs ALCOR.PA Comparison
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 338.7M. In comparison, ALCOR.PA has a market cap of 154.5M. Regarding current trading prices, IBAB.BR is priced at €11.66, while ALCOR.PA trades at €35.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 37.29, whereas ALCOR.PA's P/E ratio is -234.00. In terms of profitability, IBAB.BR's ROE is +0.09%, compared to ALCOR.PA's ROE of -0.23%. Regarding short-term risk, IBAB.BR is more volatile compared to ALCOR.PA. This indicates potentially higher risk in terms of short-term price fluctuations for IBAB.BR.
IBAB.BR vs SEQUA.BR Comparison
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 338.7M. In comparison, SEQUA.BR has a market cap of 87.8M. Regarding current trading prices, IBAB.BR is priced at €11.66, while SEQUA.BR trades at €1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 37.29, whereas SEQUA.BR's P/E ratio is -1.69. In terms of profitability, IBAB.BR's ROE is +0.09%, compared to SEQUA.BR's ROE of +2.05%. Regarding short-term risk, IBAB.BR is less volatile compared to SEQUA.BR. This indicates potentially lower risk in terms of short-term price fluctuations for IBAB.BR.
IBAB.BR vs AFME.PA Comparison
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 338.7M. In comparison, AFME.PA has a market cap of 48M. Regarding current trading prices, IBAB.BR is priced at €11.66, while AFME.PA trades at €1.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 37.29, whereas AFME.PA's P/E ratio is -3.10. In terms of profitability, IBAB.BR's ROE is +0.09%, compared to AFME.PA's ROE of -0.51%. Regarding short-term risk, IBAB.BR is less volatile compared to AFME.PA. This indicates potentially lower risk in terms of short-term price fluctuations for IBAB.BR.
IBAB.BR vs ALNOV.PA Comparison
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 338.7M. In comparison, ALNOV.PA has a market cap of 35.2M. Regarding current trading prices, IBAB.BR is priced at €11.66, while ALNOV.PA trades at €0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 37.29, whereas ALNOV.PA's P/E ratio is -0.78. In terms of profitability, IBAB.BR's ROE is +0.09%, compared to ALNOV.PA's ROE of -0.23%. Regarding short-term risk, IBAB.BR is less volatile compared to ALNOV.PA. This indicates potentially lower risk in terms of short-term price fluctuations for IBAB.BR.
IBAB.BR vs ALMDT.PA Comparison
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 338.7M. In comparison, ALMDT.PA has a market cap of 32.5M. Regarding current trading prices, IBAB.BR is priced at €11.66, while ALMDT.PA trades at €1.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 37.29, whereas ALMDT.PA's P/E ratio is -1.23. In terms of profitability, IBAB.BR's ROE is +0.09%, compared to ALMDT.PA's ROE of +0.90%. Regarding short-term risk, IBAB.BR is less volatile compared to ALMDT.PA. This indicates potentially lower risk in terms of short-term price fluctuations for IBAB.BR.
IBAB.BR vs MKEA.PA Comparison
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 338.7M. In comparison, MKEA.PA has a market cap of 30.2M. Regarding current trading prices, IBAB.BR is priced at €11.66, while MKEA.PA trades at €0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 37.29, whereas MKEA.PA's P/E ratio is -2.49. In terms of profitability, IBAB.BR's ROE is +0.09%, compared to MKEA.PA's ROE of +0.74%. Regarding short-term risk, IBAB.BR is more volatile compared to MKEA.PA. This indicates potentially higher risk in terms of short-term price fluctuations for IBAB.BR.
IBAB.BR vs ALDMS.PA Comparison
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 338.7M. In comparison, ALDMS.PA has a market cap of 26.4M. Regarding current trading prices, IBAB.BR is priced at €11.66, while ALDMS.PA trades at €1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 37.29, whereas ALDMS.PA's P/E ratio is -10.15. In terms of profitability, IBAB.BR's ROE is +0.09%, compared to ALDMS.PA's ROE of -0.25%. Regarding short-term risk, IBAB.BR is less volatile compared to ALDMS.PA. This indicates potentially lower risk in terms of short-term price fluctuations for IBAB.BR.
IBAB.BR vs ALIKO.PA Comparison
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 338.7M. In comparison, ALIKO.PA has a market cap of 21.2M. Regarding current trading prices, IBAB.BR is priced at €11.66, while ALIKO.PA trades at €1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 37.29, whereas ALIKO.PA's P/E ratio is -5.85. In terms of profitability, IBAB.BR's ROE is +0.09%, compared to ALIKO.PA's ROE of -0.17%. Regarding short-term risk, IBAB.BR is more volatile compared to ALIKO.PA. This indicates potentially higher risk in terms of short-term price fluctuations for IBAB.BR.
IBAB.BR vs ALCAR.PA Comparison
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 338.7M. In comparison, ALCAR.PA has a market cap of 19.4M. Regarding current trading prices, IBAB.BR is priced at €11.66, while ALCAR.PA trades at €0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 37.29, whereas ALCAR.PA's P/E ratio is -0.29. In terms of profitability, IBAB.BR's ROE is +0.09%, compared to ALCAR.PA's ROE of +1.40%. Regarding short-term risk, IBAB.BR is less volatile compared to ALCAR.PA. This indicates potentially lower risk in terms of short-term price fluctuations for IBAB.BR.
IBAB.BR vs ALTER.PA Comparison
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 338.7M. In comparison, ALTER.PA has a market cap of 17.3M. Regarding current trading prices, IBAB.BR is priced at €11.66, while ALTER.PA trades at €1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 37.29, whereas ALTER.PA's P/E ratio is 42.00. In terms of profitability, IBAB.BR's ROE is +0.09%, compared to ALTER.PA's ROE of -0.06%. Regarding short-term risk, IBAB.BR is less volatile compared to ALTER.PA. This indicates potentially lower risk in terms of short-term price fluctuations for IBAB.BR.
IBAB.BR vs ALTHE.PA Comparison
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 338.7M. In comparison, ALTHE.PA has a market cap of 14.7M. Regarding current trading prices, IBAB.BR is priced at €11.66, while ALTHE.PA trades at €0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 37.29, whereas ALTHE.PA's P/E ratio is -2.64. In terms of profitability, IBAB.BR's ROE is +0.09%, compared to ALTHE.PA's ROE of -1.29%. Regarding short-term risk, IBAB.BR is less volatile compared to ALTHE.PA. This indicates potentially lower risk in terms of short-term price fluctuations for IBAB.BR.
IBAB.BR vs ALEMG.PA Comparison
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 338.7M. In comparison, ALEMG.PA has a market cap of 12.9M. Regarding current trading prices, IBAB.BR is priced at €11.66, while ALEMG.PA trades at €4.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 37.29, whereas ALEMG.PA's P/E ratio is 30.33. In terms of profitability, IBAB.BR's ROE is +0.09%, compared to ALEMG.PA's ROE of +0.94%. Regarding short-term risk, IBAB.BR is more volatile compared to ALEMG.PA. This indicates potentially higher risk in terms of short-term price fluctuations for IBAB.BR.
IBAB.BR vs ALIMP.PA Comparison
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 338.7M. In comparison, ALIMP.PA has a market cap of 10M. Regarding current trading prices, IBAB.BR is priced at €11.66, while ALIMP.PA trades at €0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 37.29, whereas ALIMP.PA's P/E ratio is -2.00. In terms of profitability, IBAB.BR's ROE is +0.09%, compared to ALIMP.PA's ROE of -2.06%. Regarding short-term risk, IBAB.BR is less volatile compared to ALIMP.PA. This indicates potentially lower risk in terms of short-term price fluctuations for IBAB.BR.
IBAB.BR vs ALBLU.PA Comparison
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 338.7M. In comparison, ALBLU.PA has a market cap of 6.6M. Regarding current trading prices, IBAB.BR is priced at €11.66, while ALBLU.PA trades at €0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 37.29, whereas ALBLU.PA's P/E ratio is -5.40. In terms of profitability, IBAB.BR's ROE is +0.09%, compared to ALBLU.PA's ROE of -0.61%. Regarding short-term risk, IBAB.BR is more volatile compared to ALBLU.PA. This indicates potentially higher risk in terms of short-term price fluctuations for IBAB.BR.
IBAB.BR vs ALSGD.PA Comparison
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 338.7M. In comparison, ALSGD.PA has a market cap of 6.6M. Regarding current trading prices, IBAB.BR is priced at €11.66, while ALSGD.PA trades at €0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 37.29, whereas ALSGD.PA's P/E ratio is -1.75. In terms of profitability, IBAB.BR's ROE is +0.09%, compared to ALSGD.PA's ROE of -0.59%. Regarding short-term risk, IBAB.BR is less volatile compared to ALSGD.PA. This indicates potentially lower risk in terms of short-term price fluctuations for IBAB.BR.
IBAB.BR vs DGM.PA Comparison
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 338.7M. In comparison, DGM.PA has a market cap of 0. Regarding current trading prices, IBAB.BR is priced at €11.66, while DGM.PA trades at €1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 37.29, whereas DGM.PA's P/E ratio is -4.43. In terms of profitability, IBAB.BR's ROE is +0.09%, compared to DGM.PA's ROE of -0.35%. Regarding short-term risk, IBAB.BR is less volatile compared to DGM.PA. This indicates potentially lower risk in terms of short-term price fluctuations for IBAB.BR.